Report Code: CMI44960

Published Date: March 2024

Pages: 320+

Category: Healthcare

Report Snapshot

CAGR: 5.1%
3.1B
2023
3.3B
2024
5.1B
2033

Source: CMI

Study Period: 2024-2033
Fastest Growing Market: Asia-Pacific
Largest Market: Europe

Major Players

  • Pfizer Inc.
  • Novartis International AG
  • Merck & Co. Inc.
  • Eli Lilly and Company
  • Bristol Myers Squibb Company
  • Others

Exclusive, in-depth market intelligence can help you increase your Revenue.

Download Sample Pdf

Reports Description

As per the current market research conducted by the CMI Team, the global Cancer Cachexia Market is expected to record a CAGR of 5.1% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 3.3 Billion. By 2033, the valuation is anticipated to reach USD 5.1 Billion.

The Cancer Cachexia market refers to the segment of the healthcare industry focused on addressing the multifaceted challenges associated with cachexia in cancer patients. Cachexia, characterized by progressive weight loss, muscle wasting, and metabolic abnormalities, significantly impacts patient quality of life and clinical outcomes.

The market encompasses pharmaceutical interventions, nutritional support, exercise programs, and supportive care services aimed at mitigating cachexia-related symptoms and improving patient well-being. Key players in the market include pharmaceutical companies, biotechnology firms, healthcare providers, and research institutions, all working collaboratively to develop innovative therapies and holistic approaches to manage cancer cachexia effectively.

Cancer Cachexia Market – Significant Growth Factors

The Cancer Cachexia Market presents significant growth opportunities due to several factors:

  • Increasing Cancer Prevalence: The rising incidence of cancer globally contributes to the growth of the Cancer Cachexia market, as cachexia is a common complication in cancer patients, affecting their quality of life and treatment outcomes.
  • Advancements in Oncology Research: Ongoing advancements in oncology research have led to a deeper understanding of the molecular mechanisms underlying cancer cachexia, driving the development of targeted therapies and interventions to manage cachexia symptoms more effectively.
  • Growing Awareness and Diagnosis: Increased awareness among healthcare professionals and patients regarding the impact of cachexia on cancer management has led to earlier diagnosis and intervention, driving demand for cachexia management strategies and supportive care services.
  • Regulatory Support and Incentives: Regulatory agencies have shown a growing interest in addressing supportive care needs in cancer patients, including cachexia. Expedited pathways for drug approval and incentives for orphan drug development encourage investment in research and development targeting cancer cachexia.
  • Personalized Medicine Approaches: There is an opportunity to leverage advances in precision medicine to develop personalized treatment approaches for cancer cachexia. Tailoring therapies based on individual patient characteristics, such as tumor type, genetic profile, and metabolic status, could enhance treatment efficacy and patient outcomes.

Cancer Cachexia Market – Mergers and Acquisitions

The Cancer Cachexia Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Cancer Cachexia Market include:

  • In 2022, RTHEx biotech launched ENTRYTM, a platform facilitating tissue-enriched delivery of antimiRs. This innovation enables the advancement of its drug pipeline, targeting conditions like myotonic dystrophy, cancer cachexia, and osteoarthritis, promising improved therapeutic outcomes.
  • In 2022, Venus Remedies Limited unveils the launch of its consumer healthcare division, offering a range of products dedicated to pain management, further diversifying its portfolio and expanding its presence in the consumer health market segment.
  • In 2022, Gamida Cell’s allogeneic cell therapy Omisirge received FDA approval, promising to enhance access to stem cell transplants and improve patient outcomes. This milestone marks a significant advancement in the field of cell therapy and offers hope for patients in need of transplantation.

These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Cancer Cachexia Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Cancer Cachexia Market Pet Cancer Therapeutics Market Endometrial Cancer Market
CAGR 5.1% (Approx) CAGR 9.2% (Approx) CAGR 4.8% (Approx)
USD 5.1 Billion by 2033 USD 1,162.4 Million by 2033 USD 50.8 Billion by 2033

Cancer Cachexia Market – Significant Threats

The Cancer Cachexia Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

  • Limited Treatment Options: The lack of approved therapies specifically indicated for cancer cachexia represents a significant threat to the market. Despite ongoing research efforts, there remains a limited number of effective treatment options available to manage cachexia symptoms, resulting in unmet medical needs and challenges in addressing the complex pathophysiology of the condition.
  • High Development Costs: Developing new therapies for cancer cachexia entails substantial research and development costs, including preclinical studies, clinical trials, and regulatory approvals. The high costs associated with drug development, coupled with the uncertain success rates of clinical trials, pose a financial risk to pharmaceutical companies and may deter investment in this therapeutic area.
  • Complexity of Disease Mechanisms: Cancer cachexia is a multifactorial syndrome involving various pathological processes, including inflammation, metabolic dysregulation, and muscle wasting. The complexity of disease mechanisms presents challenges in identifying effective therapeutic targets and developing targeted interventions, limiting the progress in developing novel treatments for cachexia.
  • Under recognition and Misdiagnosis: Cancer cachexia is often underrecognized and misdiagnosed in clinical practice, leading to suboptimal management and poor patient outcomes. Healthcare providers may focus primarily on treating the underlying cancer, overlooking cachexia-related symptoms and their impact on patient well-being. This under recognition hampers efforts to raise awareness, improve diagnosis, and implement appropriate interventions for cachexia.

Global Cancer Cachexia Market 2024–2033 (By Distribution Channel)

www.custommarketinsight.com

Category-Wise Insights

By Therapeutics:

  • Progestogen: Progestogens are synthetic hormones that have been explored for their potential to alleviate cancer cachexia symptoms by modulating inflammatory pathways and promoting muscle mass preservation. Despite initial interest, clinical evidence supporting their efficacy in cachexia management remains limited.
  • Corticosteroids: Corticosteroids, such as dexamethasone and prednisone, have been used to mitigate inflammation and improve appetite in cancer cachexia patients. However, concerns regarding their adverse effects and limited long-term benefits have led to a revaluation of their role in cachexia management.
  • Combination Therapy: Combination therapies, involving the use of multiple pharmacological agents or a combination of pharmacological and non-pharmacological interventions, are being investigated for their potential synergistic effects in managing cancer cachexia. This approach aims to target multiple underlying mechanisms of cachexia simultaneously, potentially improving treatment outcomes.
  • Other Therapeutics: Various other therapeutics, including appetite stimulants, anti-inflammatory agents, anabolic agents, and nutritional supplements, are being explored for their potential in cancer cachexia management. Emerging trends include the development of targeted therapies and personalized treatment approaches tailored to individual patient characteristics and cachexia phenotypes.

Global Cancer Cachexia Market 2024–2033 (By Mechanism Of Action)

www.custommarketinsight.com

By Mechanism Of Action

  • Appetite Stimulators: Appetite stimulators are medications or interventions aimed at increasing food intake and appetite in cancer cachexia patients, addressing reduced appetite and anorexia associated with the condition. Emerging trends include the development of novel pharmacological agents and nutritional strategies targeting appetite regulation pathways to improve food intake and nutritional status in cachexia patients.
  • Weight Loss Stabilizers: Weight loss stabilizers are therapies designed to mitigate or halt the progressive loss of lean body mass and weight in cancer cachexia patients, aiming to stabilize body composition and preserve muscle mass. Current trends involve the exploration of targeted therapies and lifestyle interventions focusing on muscle protein synthesis, metabolic regulation, and physical activity to prevent or slow down weight loss progression in cachexia.
  • Others: The “Others” category encompasses various therapeutic modalities and supportive care interventions in the Cancer Cachexia market that do not fit strictly into the categories of appetite stimulators or weight loss stabilizers. This includes complementary and alternative medicine approaches, supportive care services, and palliative care interventions. Trends in this segment include the integration of digital health solutions, such as telemedicine and remote monitoring, to enhance patient support and symptom management, as well as the development of personalized medicine approaches tailored to individual patient needs and preferences.

By Distribution Channel

  • Hospital Store: Hospital stores refer to pharmacies located within hospitals or healthcare facilities that dispense medications and medical supplies to inpatients and outpatients. Trends in the Cancer Cachexia Market include increased availability of specialized cachexia therapies and supportive care services within hospital pharmacies, facilitating integrated patient care.
  • Retail Pharmacy Store: Retail pharmacy stores are community-based pharmacies that provide prescription medications and over-the-counter products to the general public. In the Cancer Cachexia Market, trends include the expansion of retail pharmacy services to offer cachexia management products, nutritional supplements, and supportive care resources, improving accessibility for patients.
  • Online Pharmacies: Online pharmacies operate via internet platforms, allowing customers to order and receive medications and healthcare products remotely. In the Cancer Cachexia Market, trends include the emergence of online pharmacies offering a range of cachexia management options, facilitating convenient access to specialized therapies and supportive care resources for patients and caregivers.

Report Scope

Feature of the Report Details
Market Size in 2024 USD 3.3 Billion
Projected Market Size in 2033 USD 5.1 Billion
Market Size in 2023 USD 3.1 Billion
CAGR Growth Rate 5.1% CAGR
Base Year 2023
Forecast Period 2024-2033
Key Segment By Therapeutics, Mechanism Of Action, Distribution Channel and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Cancer Cachexia Market – Regional Analysis

The Cancer Cachexia Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

  • North America: In North America, a significant trend in the Cancer Cachexia Market is the focus on research and development, with a high concentration of pharmaceutical companies and academic institutions conducting clinical trials and developing innovative therapies for cachexia management. Additionally, there is an increasing emphasis on integrated care models, involving multidisciplinary teams to address cachexia-related symptoms and improve patient outcomes.
  • Europe: In Europe, a notable trend in the Cancer Cachexia Market is the growing adoption of personalized medicine approaches, with efforts to tailor cachexia treatments based on individual patient characteristics and disease profiles. Moreover, there is a rising awareness of cachexia among healthcare professionals, leading to improved diagnosis and management practices across the region.
  • Asia-Pacific: In the Asia-Pacific region, a key trend in the Cancer Cachexia Market is the expanding healthcare infrastructure and access to cancer care services, particularly in emerging economies. This growth is accompanied by increased investment in supportive care programs and nutritional support services to address cachexia-related needs among cancer patients. Additionally, there is a rising demand for affordable and culturally sensitive cachexia management options in the region.
  • LAMEA (Latin America, Middle East, and Africa): In the LAMEA region, a notable trend in the Cancer Cachexia Market is the rising prevalence of cancer and cachexia, coupled with efforts to improve cancer care infrastructure and access to supportive care services. This trend is driving the adoption of innovative therapies and nutritional interventions to address cachexia-related symptoms and enhance patient well-being across diverse healthcare settings in the region.

Global Cancer Cachexia Market 2024–2033 (By Billion)

www.custommarketinsight.com

Competitive Landscape – Cancer Cachexia Market

The Cancer Cachexia Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:

  • Pfizer Inc.
  • Novartis International AG
  • Merck & Co. Inc.
  • Eli Lilly and Company
  • Bristol Myers Squibb Company
  • AstraZeneca PLC
  • Hoffmann-La Roche Ltd.
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • GlaxoSmithKline plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Sanofi SA
  • AbbVie Inc.
  • Johnson & Johnson
  • Others

These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.

Several new players have entered the Cancer Cachexia market by adopting innovative approaches to therapy development. These include biotechnology startups focusing on novel drug targets, academic spin-offs leveraging cutting-edge research, and digital health companies offering technology-driven solutions for cachexia management.

However, key players such as Pfizer, Novartis, and Merck maintain dominance through their extensive R&D capabilities, established market presence, and strategic partnerships. They lead by investing in groundbreaking research, conducting large-scale clinical trials, and securing regulatory approvals, positioning themselves as leaders in providing effective therapies for cancer cachexia.

The Cancer Cachexia Market is segmented as follows:

By Therapeutics

  • Progestogen
  • Corticosteroid
  • Combination Therapy
  • Other Therapeutics

By Mechanism Of Action

  • Appetite Stimulators
  • Weight Loss Stabilizers
  • Others

By Distribution Channel

  • Hospital Store
  • Retail Pharmacy Store
  • Online Pharmacies

Regional Coverage:

North America

  • U.S.
  • Canada
  • Mexico
  • Rest of North America

Europe

  • Germany
  • France
  • U.K.
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Taiwan
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Cancer Cachexia Market, (2024 – 2033) (USD Billion)
    • 2.2 Global Cancer Cachexia Market: snapshot
  • Chapter 3. Global Cancer Cachexia Market – Industry Analysis
    • 3.1 Cancer Cachexia Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Increasing Cancer Prevalence
      • 3.2.2 Advancements in Oncology Research
      • 3.2.3 Growing Awareness and Diagnosis
      • 3.2.4 Regulatory Support and Incentives
      • 3.2.5 Personalized Medicine Approaches.
    • 3.3 Market Restraints
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market Attractiveness Analysis By Therapeutics
      • 3.7.2 Market Attractiveness Analysis By Mechanism Of Action
      • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • Chapter 4. Global Cancer Cachexia Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Cancer Cachexia Market: Company Market Share, 2023
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Cancer Cachexia Market – Therapeutics Analysis
    • 5.1 Global Cancer Cachexia Market Overview: By Therapeutics
      • 5.1.1 Global Cancer Cachexia Market Share, By Therapeutics, 2023 and 2033
    • 5.2 Progestogen
      • 5.2.1 Global Cancer Cachexia Market by Progestogen, 2024 – 2033 (USD Billion)
    • 5.3 Corticosteroid
      • 5.3.1 Global Cancer Cachexia Market by Corticosteroid, 2024 – 2033 (USD Billion)
    • 5.4 Combination Therapy
      • 5.4.1 Global Cancer Cachexia Market by Combination Therapy, 2024 – 2033 (USD Billion)
    • 5.5 Other Therapeutics
      • 5.5.1 Global Cancer Cachexia Market by Other Therapeutics, 2024 – 2033 (USD Billion)
  • Chapter 6. Global Cancer Cachexia Market – Mechanism Of Action Analysis
    • 6.1 Global Cancer Cachexia Market Overview: By Mechanism Of Action
      • 6.1.1 Global Cancer Cachexia Market Share, By Mechanism Of Action, 2023 and 2033
    • 6.2 Appetite Stimulators
      • 6.2.1 Global Cancer Cachexia Market by Appetite Stimulators, 2024 – 2033 (USD Billion)
    • 6.3 Weight Loss Stabilizers
      • 6.3.1 Global Cancer Cachexia Market by Weight Loss Stabilizers, 2024 – 2033 (USD Billion)
    • 6.4 Others
      • 6.4.1 Global Cancer Cachexia Market by Others, 2024 – 2033 (USD Billion)
  • Chapter 7. Global Cancer Cachexia Market – Distribution Channel Analysis
    • 7.1 Global Cancer Cachexia Market Overview: By Distribution Channel
      • 7.1.1 Global Cancer Cachexia Market Share, By Distribution Channel, 2023 and 2033
    • 7.2 Hospital Store
      • 7.2.1 Global Cancer Cachexia Market by Hospital Store, 2024 – 2033 (USD Billion)
    • 7.3 Retail Pharmacy Store
      • 7.3.1 Global Cancer Cachexia Market by Retail Pharmacy Store, 2024 – 2033 (USD Billion)
    • 7.4 Online Pharmacies
      • 7.4.1 Global Cancer Cachexia Market by Online Pharmacies, 2024 – 2033 (USD Billion)
  • Chapter 8. Cancer Cachexia Market – Regional Analysis
    • 8.1 Global Cancer Cachexia Market Regional Overview
    • 8.2 Global Cancer Cachexia Market Share, by Region, 2023 & 2033 (USD Billion)
    • 8.3. North America
      • 8.3.1 North America Cancer Cachexia Market, 2024 – 2033 (USD Billion)
        • 8.3.1.1 North America Cancer Cachexia Market, by Country, 2024 – 2033 (USD Billion)
    • 8.4 North America Cancer Cachexia Market, by Therapeutics, 2024 – 2033
      • 8.4.1 North America Cancer Cachexia Market, by Therapeutics, 2024 – 2033 (USD Billion)
    • 8.5 North America Cancer Cachexia Market, by Mechanism Of Action, 2024 – 2033
      • 8.5.1 North America Cancer Cachexia Market, by Mechanism Of Action, 2024 – 2033 (USD Billion)
    • 8.6 North America Cancer Cachexia Market, by Distribution Channel, 2024 – 2033
      • 8.6.1 North America Cancer Cachexia Market, by Distribution Channel, 2024 – 2033 (USD Billion)
    • 8.7. Europe
      • 8.7.1 Europe Cancer Cachexia Market, 2024 – 2033 (USD Billion)
        • 8.7.1.1 Europe Cancer Cachexia Market, by Country, 2024 – 2033 (USD Billion)
    • 8.8 Europe Cancer Cachexia Market, by Therapeutics, 2024 – 2033
      • 8.8.1 Europe Cancer Cachexia Market, by Therapeutics, 2024 – 2033 (USD Billion)
    • 8.9 Europe Cancer Cachexia Market, by Mechanism Of Action, 2024 – 2033
      • 8.9.1 Europe Cancer Cachexia Market, by Mechanism Of Action, 2024 – 2033 (USD Billion)
    • 8.10 Europe Cancer Cachexia Market, by Distribution Channel, 2024 – 2033
      • 8.10.1 Europe Cancer Cachexia Market, by Distribution Channel, 2024 – 2033 (USD Billion)
    • 8.11. Asia Pacific
      • 8.11.1 Asia Pacific Cancer Cachexia Market, 2024 – 2033 (USD Billion)
        • 8.11.1.1 Asia Pacific Cancer Cachexia Market, by Country, 2024 – 2033 (USD Billion)
    • 8.12 Asia Pacific Cancer Cachexia Market, by Therapeutics, 2024 – 2033
      • 8.12.1 Asia Pacific Cancer Cachexia Market, by Therapeutics, 2024 – 2033 (USD Billion)
    • 8.13 Asia Pacific Cancer Cachexia Market, by Mechanism Of Action, 2024 – 2033
      • 8.13.1 Asia Pacific Cancer Cachexia Market, by Mechanism Of Action, 2024 – 2033 (USD Billion)
    • 8.14 Asia Pacific Cancer Cachexia Market, by Distribution Channel, 2024 – 2033
      • 8.14.1 Asia Pacific Cancer Cachexia Market, by Distribution Channel, 2024 – 2033 (USD Billion)
    • 8.15. Latin America
      • 8.15.1 Latin America Cancer Cachexia Market, 2024 – 2033 (USD Billion)
        • 8.15.1.1 Latin America Cancer Cachexia Market, by Country, 2024 – 2033 (USD Billion)
    • 8.16 Latin America Cancer Cachexia Market, by Therapeutics, 2024 – 2033
      • 8.16.1 Latin America Cancer Cachexia Market, by Therapeutics, 2024 – 2033 (USD Billion)
    • 8.17 Latin America Cancer Cachexia Market, by Mechanism Of Action, 2024 – 2033
      • 8.17.1 Latin America Cancer Cachexia Market, by Mechanism Of Action, 2024 – 2033 (USD Billion)
    • 8.18 Latin America Cancer Cachexia Market, by Distribution Channel, 2024 – 2033
      • 8.18.1 Latin America Cancer Cachexia Market, by Distribution Channel, 2024 – 2033 (USD Billion)
    • 8.19. The Middle-East and Africa
      • 8.19.1 The Middle-East and Africa Cancer Cachexia Market, 2024 – 2033 (USD Billion)
        • 8.19.1.1 The Middle-East and Africa Cancer Cachexia Market, by Country, 2024 – 2033 (USD Billion)
    • 8.20 The Middle-East and Africa Cancer Cachexia Market, by Therapeutics, 2024 – 2033
      • 8.20.1 The Middle-East and Africa Cancer Cachexia Market, by Therapeutics, 2024 – 2033 (USD Billion)
    • 8.21 The Middle-East and Africa Cancer Cachexia Market, by Mechanism Of Action, 2024 – 2033
      • 8.21.1 The Middle-East and Africa Cancer Cachexia Market, by Mechanism Of Action, 2024 – 2033 (USD Billion)
    • 8.22 The Middle-East and Africa Cancer Cachexia Market, by Distribution Channel, 2024 – 2033
      • 8.22.1 The Middle-East and Africa Cancer Cachexia Market, by Distribution Channel, 2024 – 2033 (USD Billion)
  • Chapter 9. Company Profiles
    • 9.1 Pfizer Inc.
      • 9.1.1 Overview
      • 9.1.2 Financials
      • 9.1.3 Product Portfolio
      • 9.1.4 Business Strategy
      • 9.1.5 Recent Developments
    • 9.2 Novartis International AG
      • 9.2.1 Overview
      • 9.2.2 Financials
      • 9.2.3 Product Portfolio
      • 9.2.4 Business Strategy
      • 9.2.5 Recent Developments
    • 9.3 Merck & Co. Inc.
      • 9.3.1 Overview
      • 9.3.2 Financials
      • 9.3.3 Product Portfolio
      • 9.3.4 Business Strategy
      • 9.3.5 Recent Developments
    • 9.4 Eli Lilly and Company
      • 9.4.1 Overview
      • 9.4.2 Financials
      • 9.4.3 Product Portfolio
      • 9.4.4 Business Strategy
      • 9.4.5 Recent Developments
    • 9.5 Bristol Myers Squibb Company
      • 9.5.1 Overview
      • 9.5.2 Financials
      • 9.5.3 Product Portfolio
      • 9.5.4 Business Strategy
      • 9.5.5 Recent Developments
    • 9.6 AstraZeneca PLC
      • 9.6.1 Overview
      • 9.6.2 Financials
      • 9.6.3 Product Portfolio
      • 9.6.4 Business Strategy
      • 9.6.5 Recent Developments
    • 9.7 F. Hoffmann-La Roche Ltd.
      • 9.7.1 Overview
      • 9.7.2 Financials
      • 9.7.3 Product Portfolio
      • 9.7.4 Business Strategy
      • 9.7.5 Recent Developments
    • 9.8 Takeda Pharmaceutical Company Limited
      • 9.8.1 Overview
      • 9.8.2 Financials
      • 9.8.3 Product Portfolio
      • 9.8.4 Business Strategy
      • 9.8.5 Recent Developments
    • 9.9 Amgen Inc.
      • 9.9.1 Overview
      • 9.9.2 Financials
      • 9.9.3 Product Portfolio
      • 9.9.4 Business Strategy
      • 9.9.5 Recent Developments
    • 9.10 GlaxoSmithKline plc
      • 9.10.1 Overview
      • 9.10.2 Financials
      • 9.10.3 Product Portfolio
      • 9.10.4 Business Strategy
      • 9.10.5 Recent Developments
    • 9.11 Bayer AG
      • 9.11.1 Overview
      • 9.11.2 Financials
      • 9.11.3 Product Portfolio
      • 9.11.4 Business Strategy
      • 9.11.5 Recent Developments
    • 9.12 Boehringer Ingelheim International GmbH
      • 9.12.1 Overview
      • 9.12.2 Financials
      • 9.12.3 Product Portfolio
      • 9.12.4 Business Strategy
      • 9.12.5 Recent Developments
    • 9.13 Sanofi SA
      • 9.13.1 Overview
      • 9.13.2 Financials
      • 9.13.3 Product Portfolio
      • 9.13.4 Business Strategy
      • 9.13.5 Recent Developments
    • 9.14 AbbVie Inc.
      • 9.14.1 Overview
      • 9.14.2 Financials
      • 9.14.3 Product Portfolio
      • 9.14.4 Business Strategy
      • 9.14.5 Recent Developments
    • 9.15 Johnson & Johnson
      • 9.15.1 Overview
      • 9.15.2 Financials
      • 9.15.3 Product Portfolio
      • 9.15.4 Business Strategy
      • 9.15.5 Recent Developments
    • 9.16 Others.
      • 9.16.1 Overview
      • 9.16.2 Financials
      • 9.16.3 Product Portfolio
      • 9.16.4 Business Strategy
      • 9.16.5 Recent Developments
List Of Figures

Figures No 1 to 26

List Of Tables

Tables No 1 to 77

Report Methodology

In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:

Preliminary Data Mining

On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.

Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.

Statistical Model

Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.

Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.

Some of the variables taken into account for forecasting are as follows:

• Industry drivers and constraints, as well as their current and projected impact

• The raw material case, as well as supply-versus-price trends

• Current volume and projected volume growth through 2032

We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.

Primary Validation

This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.

Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.

All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:

• Market leaders

• Suppliers of raw materials

• Suppliers of raw materials

• Buyers.

The following are the primary research objectives:

• To ensure the accuracy and acceptability of our data.

• Gaining an understanding of the current market and future projections.

Data Collection Matrix

Perspective Primary research Secondary research
Supply-side
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data
Demand-side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers


Market Analysis Matrix

Qualitative analysis Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2032
  • Market revenue estimates and forecasts up to 2032, by technology
  • Market revenue estimates and forecasts up to 2032, by application
  • Market revenue estimates and forecasts up to 2032, by type
  • Market revenue estimates and forecasts up to 2032, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Prominent Player

  • Pfizer Inc.
  • Novartis International AG
  • Merck & Co. Inc.
  • Eli Lilly and Company
  • Bristol Myers Squibb Company
  • AstraZeneca PLC
  • Hoffmann-La Roche Ltd.
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • GlaxoSmithKline plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Sanofi SA
  • AbbVie Inc.
  • Johnson & Johnson
  • Others

FAQs

The key factors driving the Market are Increasing Cancer Prevalence, Advancements in Oncology Research, Growing Awareness and Diagnosis, Regulatory Support and Incentives, Personalized Medicine Approaches.

The “Progestogen” category dominated the market in 2023.

The key players in the market are Pfizer Inc., Novartis International AG, Merck & Co. Inc., Eli Lilly and Company, Bristol Myers Squibb Company, AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, Amgen Inc., GlaxoSmithKline plc, Bayer AG, Boehringer Ingelheim International GmbH, Sanofi SA, AbbVie Inc., Johnson & Johnson, Others.

“North America” had the largest share in the Cancer Cachexia Market.

The global market is projected to grow at a CAGR of 5.1% during the forecast period, 2024-2033.

The Cancer Cachexia Market size was valued at USD 3.3 Billion in 2024.

PURCHASE OPTIONS

$

3490


$

4490


$

5490


$

1950


powerbi pdf
$

6200

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • Free 25% or 40 hours of customisation.
  • Free post-sale service assistance.
  • 15% discount on your next purchase.
  • Dedicated account Associate .
  • Permission to print the report.
  • Service guarantee available.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • Free 35% or 60 hours of customisation.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantee available.
  • Personalised market brief by author.
  • Permission to print the report.
  • PDF, Excel and Power Point.
  • Can be accessible by unlimited users.
  • Free 40% or 80 hours of customisation.
  • Free post-sale service assistance.
  • 30% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account manager.
  • Service guarantee available.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
  • 15% discount on your next purchase.
  • Free 20% or 10 hours of customisation.
  • PDF, Excel, Power Point and Power BI.
  • Every Year Free Update ( Apr – Apr)
  • Personalized market brief by author
  • Can be accessible by unlimited users.
  • Free 50% or 90 hours of customization.
  • Up to 50 Company Profiles
  • Free post-sale service assistance with guarantee
  • 40% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account team.
  • Service guarantee available.

Want to customize this report?
100% FREE CUSTOMIZATION!